Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
Dupixent peak sales ambition raised to more than €13 billion
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Subscribe To Our Newsletter & Stay Updated